On June 6, 2019, GRAIL announced it has hired Amgen SVP for Global Value, Access, Policy, Josh Ofman MD, as GRAIL's Chief of Corporate Strategy and External Affairs. See the press release here.
Ofman spent 16 years at Amgen. An internist, he holds an MD from UCI, his residency training at UCLA, and a master's from the School of Public Health at UCLA. See his Linked In here. See an 2018 interview with Ofman on the healthcare value of drugs here.
GRAIL also announced its current CEO has had to step down for family reasons and the new CEO will be board member Hans Bishop. Bishop was CEO of Juno Therapeutics, which Celgene acquired for $9B in 2018. See Stat here, Fierce Biotech here.
A Fierce Biotech article re GRAIL data from ASCO 2019 is here. A StatPlus article on GRAIL from ASCO is here.